Navigation Links
University of Maryland BioPark Announces MedImmune's Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
Date:4/24/2012

BALTIMORE, April 24, 2012 /PRNewswire/ -- The University of Maryland BioPark announced today that Bahija Jallal, Ph.D., Executive Vice President of Research and Development at MedImmune, has been appointed as the newest member of the UM Health Sciences Research Park Corporation (RPC) Board of Directors.

(Photo:  http://photos.prnewswire.com/prnh/20120424/PH92491 )

"The BioPark leadership team is thrilled to welcome Dr. Jallal – a seasoned life science research and development leader ­– to the Research Park Corporation's board of directors," said RPC President James Hughes, who also serves as the Vice President and Chief Enterprise & Economic Development Officer for the University of Maryland. "Her experience within leading biopharmaceutical companies will bring additional industry perspective to our project. It's a privilege to have Dr. Jallal on our board."

Dr. Jallal is a member of both MedImmune's executive team as well as the R&D leadership team of parent company AstraZeneca. She joined MedImmune as Vice President, Translational Sciences, in March 2006 and has since held positions of increasing responsibility. Dr. Jallal now oversees research, development, regulatory and clinical activities conducted by a team of more than 2,500 employees based at MedImmune's Maryland, California, and Cambridge, UK sites. Dr. Jallal has guided the MedImmune R&D organization through unprecedented growth and expansion of its biologics pipeline from 40 drugs to more than 140. Dr. Jallal is passionate about leading and shaping MedImmune's rich pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardio-vascular and gastrointestinal disorders and pain to ultimately develop new medicines for patients.

Of her new role on the RPC board, Dr. Jallal said, "When you visit the UM BioPark, you can't help but be impressed by the clear marriage of industry and academia that exists at this hub of innovation. I'm honored to serve as a board member and look forward to sharing my industry perspective while participating with an organization that stands strong in its commitment to give back to the local Baltimore community while at the same time fostering business and scientific opportunities for industry."

In addition to working with the State of Maryland as a board member for the UM Health Sciences RPC, Dr. Jallal participated last year in Maryland Governor O'Malley's Trade Mission to India where she represented the life sciences. She has authored more than 60 peer-reviewed publications and has over 15 patents. She is a member of multiple research associations and organizations promoting women in science. In 2011 she was named one of FierceBiotech's Top Women in Biotech.

Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as Vice President, Drug Assessment and Development, and successfully established the company's translational medicine group.  Prior to Chiron Corporation, she worked at Sugen, Inc. where she held positions of increasing responsibility leading to Senior Director, Research.

Dr. Jallal received a master's degree in biology from the Universite de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.

About the University of Maryland BioPark

The mission of the BioPark is to create a university-associated research park that accelerates biotechnology commercialization and economic development in the surrounding community and throughout the region. The non-profit corporation, the University of Maryland Health Sciences Research Park Corporation, was established in 2003 and its 11-member private sector Board oversees the growth and ongoing development of the 12-acre project. Learn more at www.umbiopark.com.


'/>"/>
SOURCE The University of Maryland BioPark
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Professor Vishnu Chaturvedi of New York, USA Gives a Lecture at West China Hospital of Sichuan University
2. HUYA Bioscience Announces New Partnership with a High Profile Pharmaceutical Lab at Shanghais Prestigious Fudan University
3. Biospace Lab and the Centre for Advanced Biomedical Imaging at University College London to Collaborate on Development of Novel Real-Time in Vivo Optical Imaging Technologies
4. Sigma® Life Science Obtains Global License for Kyoto Universitys iPS Cell Patent Portfolio, Deepens Commitment to Drug Discovery and ADME/Toxicology
5. Delcath Announces Agreement With University Medical Center Schleswig-Holstein for Use of Its Hepatic CHEMOSAT Delivery System
6. PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust
7. StatVideo LLC Manufactures EchoBox at University of Massachusetts Lowell
8. Delcath Announces Agreement With the Frankfurt University Hospital for Launch of Hepatic CHEMOSAT Delivery System in Germany
9. Waters Gifts Research Equipment to University at Buffalo to Combat HIV/AIDS
10. New Stage of Scientific Development for St.Petersburg State University Marked by Signed Agreement With Elsevier
11. Minority Residents Living Healthier by Working with Duquesne University Pharmacy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
(Date:6/8/2017)... 2017  Less than a month ago, amateur hackers ... companies, including hospital networks, in over 150 countries. ... the largest online extortion attempts ever recorded. With the ... is imperative that providers understand where the risks lie, ... — and many other very real cyber threats.  ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... of two Phase 2 trials of its RSV F protein ... child bearing age have been published in the journal ... have been shared in prior scientific conferences). The Company previously ... April 2014. Novavax is developing the RSV F Vaccine with ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory ... hygiene symposium in Mystic, CT. Covering the process and maintenance strategies of gum ... these popular periodontal procedures. Drs. Toback and Urbanski practice as experienced periodontists ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... . Orthodontics is a dental specialty that focuses on treating alignment and occlusion ... improved aesthetics and function. , North Hollywood dentist , Dr. Garemani, ...
(Date:6/26/2017)... ... ... Center is now offering various types of dental implants to restore lost teeth. Dental implants ... such as crowns, bridges, or dentures. An implant is placed directly into the jawbone where ... tooth. , Several types of dental implants are available, including: , ...
(Date:6/26/2017)... Ruidoso, New Mexico (PRWEB) , ... June 26, ... ... sexual dysfunction, anorgasmia, and urinary leakage is revolutionizing the way women look and ... Mexico is tackling the problem of female sexual dysfunction and urinary leakage head ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... New patients ... from Dr. Angela Cotey, with or without a referral. Dr. Cotey is a trusted ... of this preferred tooth replacement option. , Patients with missing teeth in Fitchburg, WI, ...
Breaking Medicine News(10 mins):